GlaxoSmithKline Consumer Nigeria Plc reported earnings results for the third quarter and nine months of 2017. For the quarter, the company reported turnover of £7,843 million compared to £7,542 million a year ago. Operating profit was £1,877 million compared to £1,431 million a year ago. Profit before taxation was £1,711 million compared to £1,274 million a year ago. Profit after taxations for the period was £1,395 million compared to £885 million a year ago. Profit attributable to shareholders was £1,212 million compared to £808 million a year ago. Diluted earnings per share were 24.6 pence compared to 16.5 pence a year ago. Adjusted operating profit was £2,468 million. Adjusted earnings per share were 32.5 pence. Free cash flow was £1,276 million.

For the nine months, the company reported turnover of £22,547 million compared to £20,303 million a year ago. Operating profit was £3,575 million compared to £2,003 million a year ago. Profit before taxation was £3,083 million compared to £1,516 million a year ago. Profit after taxations for the period was £2,532 million compared to £745 million a year ago. Profit attributable to shareholders was £2,078 million compared to £655 million a year ago. Diluted earnings per share were 42.1 pence compared to 13.4 pence a year ago. Net cash inflow from operating activities was £4,049 million compared to £3,506 million a year ago. Purchase of property, plant and equipment was £1,011 million compared to £943 million a year ago. Purchase of intangible assets was £513 million compared to £648 million a year ago. Adjusted operating profit was £6,530 million. Adjusted earnings per share were 84.6 pence. Free cash flow was £1,644 million.

The company earnings guidance for 2017, the company expects adjusted earnings per share growth maintained at 3% to 5% CER.